The Food and Drug Administration recently issued a warning to Allergan Inc., stating that the website for Latisse (a prescription eyelash lengthener) is misleading because it omits and minimizes risks associated with the product.

In a letter dated September 10, the FDA warns that misbrands Latisse – in violation of the Federal Food, Drug, and Cosmetic Act – because it does not clearly convey the consequences that may result from use of the drug, which include:

Iris pigmentation
Lid pigmentation
Hair growth outside the treatment area
Intraocular inflammation
Potential for contamination and infections
Absorption by soft contact lenses

To read the letter in its entirety, .

by // Comments Off on FDA Lashes Out at Latisse

Comments are closed.